New GSK WKN: A3DMB5 ISIN: GB00BN7SWP63 Forum: Aktien User: o2kuh

Kriegen wir die 15,66 € nochmal?

15,82 EUR +0,76 % +0,12

+0.5% 15.78€

Geld 15,63 / Brief 15,75

Wer hat gerade zu 15,735 € gekauft?!

15,79 EUR -4,30 % -0,71

15,64 EUR -5,01 % -0,83

Warum die heftige Reaktion? Es war doch klar, dass es schwierig wird

Bei Stock3 in der App als Kurznachricht 😉

Deal:)

Nichts für ungut... Aber wenn man hier in das forum schaut und dein (sinnloses) Gespamme alle paar Minuten sieht, gehörst du damit schon in die Kategorie -> verhaltensauffällig. Kümmere dich vielleicht erstmal darum/ um dich, bevor du dich mit Aktien auseinander setzt.

Hoher Spread!

15,75 €

Bitte um Link(s)

Wo hattest du das so schnell gefunden?

A group of independent advisors to the U.S. Food and Drug Administration (FDA) on Thursday voted against the approval of a combination drug regimen involving GSK’s (NYSE:GSK) blood cancer medicine Blenrep. Shares of the British pharma giant lost ~5% in reaction. The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 5-3 against the benefit-risk profile of Blenrep in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma as a late-line therapy. The panelists voted 7-1 against the drug’s benefit-risk profile with pomalidomide and dexamethasone for the same indication. Bortezomib and pomalidomide are FDA-approved cancer drugs marketed by Johnson & Johnson (JNJ) and Bristol Myers (BMY) as Velcade and Pomalyst, respectively. Dexamethasone is a widely used anti-inflammatory agent. The London-based drugmaker's Biologics License Application, targeted at getting U.S. approval for the combination drug for R/R multiple myeloma as a late-line therapy, is currently under FDA review with a target action date of July 23. The FDA's advisory committees issue non-binding recommendations. However, the regulator generally follows them before making a final decision on authorizations.